- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Modus Therapeutics Holding AB: Modus Therapeutics publishes year-end report for 2025 | 961 | GlobeNewswire (Europe) | STOCKHOLM, SWEDEN - 25 February 2026: Modus Therapeutics Holding AB ("Modus Therapeutics") hereby publishes year-end report for 2025. The report is available on the company's website (www.modustx.com)... ► Artikel lesen | |
| 10.12.25 | Karolinska Development AB (publ): Karolinska Development's portfolio company Modus Therapeutics initiates dosing in phase 2a study in patients with chronic kidney disease with anemia | 195 | GlobeNewswire (Europe) | STOCKHOLM, SWEDEN December 10, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company, Modus Therapeutics, has dosed the first patient in the phase 2a... ► Artikel lesen | |
| MODUS THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 26.11.25 | Modus Therapeutics Holding AB: Modus Therapeutics publishes Interim report for the third quarter 2025 | 419 | GlobeNewswire (Europe) | STOCKHOLM, SWEDEN - 26 November 2025: Modus Therapeutics Holding AB ("Modus Therapeutics") hereby publishes an interim report for the third quarter of 2025. The report is available on the company's... ► Artikel lesen | |
| 04.11.25 | Karolinska Development AB (publ): Karolinska Development's portfolio company Modus Therapeutics receives approval for second part of phase 2 study in chronic kidney disease with anemia | 202 | GlobeNewswire (Europe) | STOCKHOLM, SWEDEN November 4, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company, Modus Therapeutics, has received regulatory approval to initiate... ► Artikel lesen | |
| 03.11.25 | Modus Therapeutics Holding AB: Modus Therapeutics receives regulatory approval for Part 2 of the Phase IIa study in CKD-with anemia | 216 | GlobeNewswire (Europe) | Stockholm, Sweden - November 3, 2025- Modus Therapeutics Holding AB (publ) ("Modus" or the "Company") announces that the competent authorities in Italy have approved the Company's dose selection for... ► Artikel lesen | |
| 28.08.25 | Karolinska Development AB (publ): Karolinska Development's portfolio company Modus Therapeutics raises SEK 28.3 million in oversubscribed unit issue | 115 | GlobeNewswire (Europe) | STOCKHOLM, SWEDEN August 28, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company, Modus Therapeutics, has raised SEK 28.3 million in a unit issue with... ► Artikel lesen | |
| 07.08.25 | Modus Therapeutics Holding AB: Modus Therapeutics publishes Interim report for the second quarter 2025 | 396 | GlobeNewswire (Europe) | STOCKHOLM, SWEDEN - 7 August 2025: Modus Therapeutics Holding AB ("Modus Therapeutics") hereby publishes an interim report for the second quarter of 2025. The report is available on the company's website... ► Artikel lesen | |
| 06.08.25 | XFRA CAPITAL ADJUSTMENT INFORMATION - 06.08.2025 | 438 | Xetra Newsboard | Das Instrument 9YG NO0010955917 DEEP VAL.DRILL.AS NK -,10 EQUITY wird cum Kapitalmassnahme gehandelt am 06.08.2025 und ex Kapitalmassnahme am 07.08.2025 The instrument 9YG NO0010955917 DEEP VAL.DRILL.AS... ► Artikel lesen | |
| 01.08.25 | Modus Therapeutics Holding AB: Modus Therapeutics on track to initiate Part 2 of Phase IIa sevuparin study in CKD-related anemia | 358 | GlobeNewswire (Europe) | Stockholm, Sweden - 1 August 2025 - Modus Therapeutics Holding AB (publ) ("Modus") today announces that dose levels for Part 2 of its ongoing Phase IIa clinical study of sevuparin in patients with chronic... ► Artikel lesen | |
| 29.07.25 | Modus Therapeutics Holding AB: Extraordinary General Meeting in Modus Therapeutics Holding AB (publ) | 209 | GlobeNewswire (Europe) | Modus Therapeutics' Extraordinary General Meeting on 29 July 2025 resolved in accordance with the following:
To amend the company's articles of association in order to increase the limits of the company's... ► Artikel lesen | |
| 14.07.25 | Karolinska Development AB (publ): Karolinska Development's portfolio company Modus Therapeutics completes enrollment in part 1 of its phase 2a study with sevuparin | 367 | GlobeNewswire (Europe) | STOCKHOLM, SWEDEN July 14, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Modus Therapeutics has completed patient enrollment on schedule to part... ► Artikel lesen | |
| 08.07.25 | Modus Therapeutics Holding AB: Modus Therapeutics completes enrollment in Part 1 of the Phase IIa sevuparin study in chronic kidney disease with anemia | 253 | GlobeNewswire (Europe) | Stockholm, Sweden - 8 July 2025 - Modus Therapeutics Holding AB (publ) ("Modus") today announces that patient enrollment in Part 1 of its ongoing Phase IIa study evaluating sevuparin for the treatment... ► Artikel lesen | |
| 27.06.25 | Karolinska Development AB (publ): Karolinska Development's portfolio company Modus Therapeutics carries out a fully secured rights issue of SEK 28.3 million | 59 | GlobeNewswire (Europe) | STOCKHOLM, SWEDEN June 27, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company, Modus Therapeutics carries out a fully secured rights issue of units... ► Artikel lesen | |
| 14.05.25 | Modus Therapeutics Holding AB: Modus Therapeutics publishes Interim report for the first quarter 2025 | 527 | GlobeNewswire (Europe) | STOCKHOLM, SWEDEN - 14 May 2025: Modus Therapeutics Holding AB ("Modus Therapeutics") hereby publishes an interim report for the first quarter of 2025. The report is available on the company's website... ► Artikel lesen | |
| 02.04.25 | Modus Therapeutics Holding AB: Modus Therapeutics opens second study site in ongoing Phase IIa CKD-anemia study | 207 | GlobeNewswire (Europe) | STOCKHOLM, SWEDEN - April 2, 2025: Modus Therapeutics Holding AB ("Modus"), a company developing innovative treatments for patients with significant unmet medical needs, today announced the opening... ► Artikel lesen |
15 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NANOREPRO | 1,525 | -2,56 % | NanoRepro zündet die nächste Story: Mit PHLAS startet der Sprung ins Premium-SkinTech-Geschäft | NanoRepro geht den nächsten strategischen Schritt - und der hat mit klassischen Selbsttests nur noch am Rand zu tun: Mit dem offiziellen Marktstart des Kaltplasmageräts "PHLAS" und dem Livegang des... ► Artikel lesen | |
| MARINOMED BIOTECH | 18,100 | 0,00 % | Marinomed-Aktie: Ist das eine ganz heiße Wette? | Wenn die Aktie eines Biotech-Unternehmens wie die der österreichischen Marinomed ein Kursdebakel erlebt und binnen fünf Jahren fast -90% an Wert verliert, dann ist das ein für diesen Sektor typisches... ► Artikel lesen | |
| REPLENISH NUTRIENTS | 0,059 | -3,30 % | Replenish Nutrients Holding Corp: Replenish Nutrients hires Sophic Capital for IR | ||
| SANA BIOTECHNOLOGY | 4,145 | -1,54 % | Sana Biotechnology (SANA) Appoints Industry Veteran Brian Piper as New CFO | ||
| NOVABRIDGE BIOSCIENCES | 2,780 | 0,00 % | NovaBridge Biosciences: NovaBridge Appoints Biotech Leader, Emmett T. Cunningham, Jr, MD, PhD, MPH, as Vice Chairman of the Board to Further Accelerate Global Biotech Platform | Appointment is a positive endorsement of NovaBridge's unique hub-and-spoke model and focus on creating shareholder value by accelerating the development of transformative medicines for patients around... ► Artikel lesen | |
| GENEURO | 0,000 | -100,00 % | GeNeuro SA Announces the End of the Debt Moratorium and the Commencement of Bankruptcy Proceedings | Regulatory News:
GeNeuro SA (Euronext Paris: CH0308403085 GNRO), a biopharmaceutical company developing novel treatments for neurodegenerative and autoimmune diseases, announces that the Geneva... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 9,340 | 0,00 % | Vir Biotechnology +70%: Deal-Überraschung mit Ansage | Die Aktie von Vir Biotechnology ist vorbörslich um rund 70 Prozent nach oben geschossen. Auslöser der Kursexplosion ist vor allem ein milliardenschwerer Kooperationsdeal mit dem japanischen Pharmakonzern... ► Artikel lesen | |
| ARCELLX | 114,05 | +0,22 % | Aktien New York Ausblick: Leichte Verluste nach Trumps Zollankündigung | NEW YORK (dpa-AFX) - Die US-Börsen steuern am Montag vor dem Hintergrund neuer Zollunsicherheit auf einen etwas tieferen Handelsauftakt zu. Nachdem der Oberste Gerichtshof der USA dem Präsidenten Donald... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 90,10 | -1,38 % | Morgan Stanley cuts Kymera Therapeutics stock price target on pipeline progress | ||
| BEAM THERAPEUTICS | 28,690 | +0,74 % | Beam Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Announces New Liver-Targeted Genetic Disease Program in Phenylketonuria (PKU) | New Program Designed as Platform-based Approach for Direct Correction of Mutations Causing PKU; Investigational New Drug (IND) Filing for BEAM-304 Anticipated in 2026 Updated Phase 1/2 Data and Next... ► Artikel lesen | |
| QIAGEN | 41,295 | -0,23 % | flatexDEGIRO, Qiagen, Börse München - 4investors-Weekend | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Und welche Titel haben besonders starke Kursbewegungen verzeichnet? Vor allem für Trader ist es wichtig zu wissen... ► Artikel lesen | |
| VERA THERAPEUTICS | 40,420 | -0,98 % | Vera Therapeutics, Inc. - 10-K, Annual Report | ||
| ARCUTIS BIOTHERAPEUTICS | 24,760 | -8,25 % | Arcutis Biotherapeutics, Inc.: Arcutis Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update | Q4 2025 net product revenue for ZORYVE (roflumilast) was $127.5 million, an 84% increase compared to Q4 2024, and a 29% increase compared to Q3 2025Full year 2025 net product revenue for ZORYVE was... ► Artikel lesen | |
| ERASCA | 14,530 | +6,45 % | Erasca, Inc.: Erasca Announces Issuance of a U.S. Patent Covering Pan-KRAS Inhibitor ERAS-4001 | The issued patent provides intellectual property protection for ERAS-4001 and related compositions until at least 2043 Expands Erasca's diversified IP portfolio for RAS-driven cancers Initial Phase... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 3,630 | 0,00 % | Recursion Pharmaceuticals: Recursion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update | Delivered first clinical validation of the Recursion full stack AI Operating System in FAP, demonstrating translation from AI-driven biological insight to meaningful patient outcomes; multiple clinical... ► Artikel lesen |
MODUS THERAPEUTICS HOLDING AB gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -12,99 % bei einem Aktienkurs von 0,013 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MODUS THERAPEUTICS HOLDING AB finden Sie auf Wallstreet Online.